MCID: DFF019
MIFTS: 46

Diffuse Gastric Cancer

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Diffuse Gastric Cancer

MalaCards integrated aliases for Diffuse Gastric Cancer:

Name: Diffuse Gastric Cancer 53
Signet Ring Cell Gastric Carcinoma 53
Diffuse Gastric Cancer Syndrome 29
Signet Ring Gastric Carcinoma 53
Gastric Signet Ring Carcinoma 72
Carcinoma, Signet Ring Cell 72
Signet Ring Cell Carcinoma 53
Signet Cell Adenocarcinoma 53
Cancer, Gastric, Diffuse 40

Classifications:



External Ids:

UMLS 72 C0206696 C2064167

Summaries for Diffuse Gastric Cancer

NIH Rare Diseases : 53 Diffuse gastric cancer or signet ring cell cancer is a type of cancer found most often in the glandular cells lining the stomach, but can also develop in the bowel, breast, pancreas, bladder, prostate or lung. The 2010 WHO (World Health Organization) classification recognizes four major histologic patterns of gastric cancers: tubular, papillary, mucinous and poorly cohesive (including signet ring cell carcinoma), plus uncommon histologic variants. The term "signet ring cell" is often used because the cells look like signet rings when viewed under a microscope. The signet cells are a type of epithelial cell. Epithelial tissue is skin tissue, covering and lining the body both inside and out. When diffuse gastric cancer is inherited it is called "hereditary diffuse gastric cancer." Treatment depends on the stage at which the cancer is found and may include chemotherapy, radiation therapy, or operations to remove the stomach (gastrectomy).

MalaCards based summary : Diffuse Gastric Cancer, also known as signet ring cell gastric carcinoma, is related to gastric cancer, hereditary diffuse and crohn's colitis. An important gene associated with Diffuse Gastric Cancer is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Tegafur and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and prostate, and related phenotypes are Decreased cell migration and Increased cell migration

Related Diseases for Diffuse Gastric Cancer

Diseases in the Diffuse Gastric Cancer family:

Gastric Cancer, Hereditary Diffuse

Diseases related to Diffuse Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
# Related Disease Score Top Affiliating Genes
1 gastric cancer, hereditary diffuse 33.5 KRAS CTNNA1 CDH1
2 crohn's colitis 30.4 CDH3 CDH1
3 gastrointestinal system cancer 30.1 KRAS CDH1
4 bronchiolo-alveolar adenocarcinoma 30.0 KRAS CDH1
5 intrahepatic cholangiocarcinoma 29.9 KRAS CDH1
6 gallbladder cancer 29.8 KRAS CDH1
7 familial adenomatous polyposis 29.7 KRAS CDH1
8 colorectal adenocarcinoma 29.6 KRAS CDH1
9 cholangiocarcinoma 29.4 KRAS CTNNA1 CDH1
10 bile duct signet ring cell carcinoma 12.7
11 pancreatic signet ring cell adenocarcinoma 12.1
12 prostate signet ring cell adenocarcinoma 12.0
13 ampullary signet ring cell adenocarcinoma 12.0
14 breast signet ring cell adenocarcinoma 12.0
15 gastric cancer 11.9
16 gallbladder signet ring cell adenocarcinoma 11.9
17 krukenberg carcinoma 11.8
18 prostate cancer 11.8
19 prostate cancer, hereditary, 1 11.5
20 prostate cancer, hereditary, 12 11.5
21 prostate cancer, hereditary, 13 11.5
22 prostate cancer, hereditary, 11 11.5
23 prostate cancer, hereditary, 2 11.5
24 mucinous adenocarcinoma 10.8
25 rare tumor 10.7
26 appendix adenocarcinoma 10.7
27 obstructive jaundice 10.6
28 bladder cancer 10.5
29 tubular adenocarcinoma 10.5
30 transitional cell carcinoma 10.5
31 adenoma 10.5
32 eyelid carcinoma 10.4
33 signet ring cell adenocarcinoma 10.4
34 rectum cancer 10.4
35 colorectal cancer 10.4
36 respiratory failure 10.4
37 disseminated intravascular coagulation 10.4
38 hemopericardium 10.4
39 pericardial effusion 10.4
40 appendicitis 10.4
41 intestinal obstruction 10.4
42 thrombotic microangiopathy 10.4
43 pancreatic cancer 10.3
44 hydronephrosis 10.3
45 cardiac tamponade 10.3
46 hemolytic anemia 10.3
47 ileus 10.3
48 gastric adenocarcinoma 10.3
49 breast cancer 10.3
50 renal cell carcinoma, nonpapillary 10.3

Graphical network of the top 20 diseases related to Diffuse Gastric Cancer:



Diseases related to Diffuse Gastric Cancer

Symptoms & Phenotypes for Diffuse Gastric Cancer

GenomeRNAi Phenotypes related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.13 CDH3 CTNNA1 KRAS
2 Increased cell migration GR00055-A-3 8.8 CDH3 CTNNA1 KRAS

MGI Mouse Phenotypes related to Diffuse Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.26 CDH1 CDH3 CTNNA1 KRAS
2 integument MP:0010771 8.92 CDH1 CDH3 CTNNA1 KRAS

Drugs & Therapeutics for Diffuse Gastric Cancer

Drugs for Diffuse Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
4
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
leucovorin Approved Phase 3 58-05-9 143 6006
7
Bevacizumab Approved, Investigational Phase 3 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
9
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
11
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
12
Camptothecin Experimental Phase 3 7689-03-4
13 Formyltetrahydrofolates Phase 3
14 Topoisomerase Inhibitors Phase 3
15 Tetrahydrofolates Phase 3
16 topoisomerase I inhibitors Phase 3
17 Antibodies Phase 3
18 Immunoglobulins Phase 3
19 Antibodies, Monoclonal Phase 3
20 Cola Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Immunologic Factors Phase 3
23 Angiogenesis Inhibitors Phase 3
24 Immunoglobulin G Phase 3
25 Micronutrients Phase 3
26 Antidotes Phase 3
27 Mitogens Phase 3
28 Vitamins Phase 3
29 Trace Elements Phase 3
30 Angiogenesis Modulating Agents Phase 3
31 Vitamin B9 Phase 3
32 Hematinics Phase 3
33 Folate Phase 3
34 Protective Agents Phase 3
35 Immunosuppressive Agents Phase 3
36 Vitamin B Complex Phase 3
37 Nutrients Phase 3
38 Calcium, Dietary Phase 3
39 Bone Density Conservation Agents Phase 3
40 Endothelial Growth Factors Phase 3
41 Protein Kinase Inhibitors Phase 3
42 Antimetabolites Phase 3
43 Antimetabolites, Antineoplastic Phase 3
44
Apatinib Phase 3 811803-05-1
45
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
46
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
47
Turmeric Approved, Experimental, Investigational Phase 2
48
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
49
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy Unknown status NCT01285557 Phase 3 S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm);Fluorouracil/cisplatin (control arm)
2 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
3 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
4 A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection. Not yet recruiting NCT03355612 Phase 3 Apatinib;XELOX
5 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Unknown status NCT01802320 Phase 2 Akt Inhibitor MK2206
6 Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome Recruiting NCT03648879 Phase 2
7 Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Recruiting NCT03620643 Phase 2 Crizotinib Oral Capsule [Xalkori];Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex]
8 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Active, not recruiting NCT00745134 Phase 2 Capecitabine
9 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Suspended NCT02978625 Phase 2
10 Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors Recruiting NCT03476681 Phase 1 NEO-201
11 Phase I Study: Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer as Adjuvant Setting (NORDICA) Not yet recruiting NCT03977220 Phase 1 Nab-paclitaxel combined with S-1
12 Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer Terminated NCT01198535 Phase 1 Gamma-Secretase Inhibitor RO4929097
13 Prospective Study of Colorectal Cancer Comparing the Surface With the Invasive Front Unknown status NCT02002299
14 Screening for Familial Gastric Cancer in First Degree Relatives Unknown status NCT01727908
15 Epidemiological, Clinical and Pathological Characteristics of Gastric Tumors. The Population Based Specialized Registry in Northern Italy Unknown status NCT01662739
16 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859
17 Single-bite Versus Double-bite Technique for Mapping Biopsies During Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer: a Single Center, Randomized Controlled Trial Completed NCT03950908
18 Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior Completed NCT01824966
19 Efficacy of Narrow Band Imaging Technique for Identifying Resection Margin Status After Gastrectomy for Gastric Cancer Completed NCT02926716
20 Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer Recruiting NCT03030404
21 The Metabolic Consequences of Gastrointestinal Surgery Terminated NCT02836353 Somatostatin;Rifaximin
22 Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer Withdrawn NCT02594943

Search NIH Clinical Center for Diffuse Gastric Cancer

Genetic Tests for Diffuse Gastric Cancer

Genetic tests related to Diffuse Gastric Cancer:

# Genetic test Affiliating Genes
1 Diffuse Gastric Cancer Syndrome 29

Anatomical Context for Diffuse Gastric Cancer

MalaCards organs/tissues related to Diffuse Gastric Cancer:

41
Breast, Skin, Prostate, Lung, Pancreas, Testes, Colon

Publications for Diffuse Gastric Cancer

Articles related to Diffuse Gastric Cancer:

(show top 50) (show all 425)
# Title Authors PMID Year
1
British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. 38
31278206 2019
2
Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil. 38
30895400 2019
3
c-Met-dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis. 38
31056743 2019
4
Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer. 38
29577179 2019
5
Hereditary Gastrointestinal Cancer Syndromes: Role of Imaging in Screening, Diagnosis, and Management. 38
31373866 2019
6
Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. 38
31296550 2019
7
Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. 38
30542785 2019
8
Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. 38
30515673 2019
9
Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer. 38
30935944 2019
10
Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. 38
31273560 2019
11
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. 38
30870726 2019
12
Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America. 38
31174492 2019
13
Optimal Timing of Total Gastrectomy to Prevent Diffuse Gastric Cancer in Individuals with Pathogenic Variants in CDH1. 38
31220641 2019
14
Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. 38
31246251 2019
15
The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome. 38
31249446 2019
16
Evaluation of confocal endoscopic microscopy for detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome. 38
31183189 2019
17
Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). 38
30745422 2019
18
Establishing a center of excellence for hereditary diffuse gastric cancer syndrome. 38
30618047 2019
19
Early Hereditary Diffuse Gastric Cancer (eHDGC) is Characterized by Subtle Genomic Instability and Active DNA Damage Response. 38
30547291 2019
20
Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature. 38
30306390 2019
21
The benefits of a model of interval comprehensive assessments (MICA) in hereditary cancer Syndromes: Hereditary diffuse gastric cancer (HDGC) as an example. 38
31109593 2019
22
Clinical spectrum and pleiotropic nature of CDH1 germline mutations. 38
30661051 2019
23
Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. 38
30302652 2019
24
Immunistochemical Analysis of the Expression of TGFβ, Galectin-1, Vimentin, and Thrombospondin in Gastric Cancer Associated with Systemic Undifferentiated Connective Tissue Dysplasia. 38
31028580 2019
25
INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. 38
30871613 2019
26
E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. 38
30066183 2019
27
Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary diffuse gastric cancer? 38
30466290 2019
28
[Hereditary diffuse gastric cancer : case serie of 8 patients from a single family and literature review]. 38
30897312 2019
29
Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report. 38
31028995 2019
30
Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. 38
29589180 2019
31
Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. 38
31058107 2019
32
CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. 38
30642281 2019
33
Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. 38
29192740 2018
34
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. 38
29714649 2018
35
Multiple Gastrointestinal Cancers in a Single Patient-a Rare Clinical Entity. 38
30538406 2018
36
Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. 38
30014492 2018
37
Molecular biology as a tool for the treatment of cancer. 38
30006681 2018
38
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. 38
30311375 2018
39
Hereditary Diffuse Gastric Cancer: More than What Meets the Endoscopic Eye. 38
30937153 2018
40
Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer. 38
30145018 2018
41
[Advances in the research of gastric signet ring cell carcinoma]. 38
30370520 2018
42
Characterization of long non-coding RNAs and MEF2C-AS1 identified as a novel biomarker in diffuse gastric cancer. 38
30005210 2018
43
RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. 38
30361512 2018
44
Clinical and functional characterization of the CDH1 germline variant c.1679C>G in three unrelated families with hereditary diffuse gastric cancer. 38
29769627 2018
45
E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer. 38
30068367 2018
46
[Outcomes after Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer]. 38
30068014 2018
47
Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. 38
30115886 2018
48
A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay. 38
29798843 2018
49
Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. 38
29706558 2018
50
Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series. 38
30007404 2018

Variations for Diffuse Gastric Cancer

Cosmic variations for Diffuse Gastric Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM18876 APC breast,NS,carcinoma,tubular c.3316G>T p.G1106* 5:112838910-112838910 3
2 COSM18885 APC breast,NS,carcinoma,tubular c.4495G>T p.G1499* 5:112840089-112840089 3
3 COSM18883 APC breast,NS,carcinoma,tubular c.4390G>T p.E1464* 5:112839984-112839984 3
4 COSM18881 APC breast,NS,carcinoma,tubular c.5047G>T p.E1683* 5:112840641-112840641 3

Expression for Diffuse Gastric Cancer

Search GEO for disease gene expression data for Diffuse Gastric Cancer.

Pathways for Diffuse Gastric Cancer

Pathways related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 KRAS CTNNA1 CDH3 CDH1 CCL7
2
Show member pathways
12.86 KRAS CTNNA1 CDH1 CCL7
3
Show member pathways
12.66 KRAS CTNNA1 CDH1
4
Show member pathways
12.59 KRAS CTNNA1 CDH1
5
Show member pathways
12.54 KRAS CTNNA1 CDH1
6 12.51 KRAS CTNNA1 CDH1
7
Show member pathways
12.42 KRAS CTNNA1 CDH1
8
Show member pathways
12.37 KRAS CTNNA1 CDH1
9
Show member pathways
12.35 CTNNA1 CDH3 CDH1
10
Show member pathways
12.06 KRAS CTNNA1 CDH1
11 12.01 CTNNA1 CDH3 CDH1
12
Show member pathways
11.91 KRAS CTNNA1 CCL7
13 11.78 KRAS CDH1
14
Show member pathways
11.73 KRAS CDH1 CCL7
15
Show member pathways
11.62 CTNNA1 CDH3 CDH1
16 11.59 CTNNA1 CDH3 CDH1
17 11.47 CTNNA1 CDH1
18 11.46 KRAS CDH1
19 11.44 CTNNA1 CDH1
20 11.42 KRAS CDH3 CDH1
21 11.22 CTNNA1 CDH3 CDH1
22 11.19 CTNNA1 CDH1
23 11.13 CTNNA1 CDH1
24 10.98 CTNNA1 CDH1
25 10.8 CTNNA1 CDH1
26 10.7 CDH3 CDH1 CCL7
27 10.65 CTNNA1 CDH1
28 10.44 CTNNA1 CDH1
29 10.4 CTNNA1 CDH3 CDH1

GO Terms for Diffuse Gastric Cancer

Cellular components related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 9.16 CTNNA1 CDH1
2 cell-cell adherens junction GO:0005913 9.13 CTNNA1 CDH3 CDH1
3 catenin complex GO:0016342 8.8 CTNNA1 CDH3 CDH1

Biological processes related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.54 CTNNA1 CDH3 CDH1
2 calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules GO:0016339 9.32 CDH3 CDH1
3 cell-cell junction assembly GO:0007043 9.26 CDH3 CDH1
4 cell-cell adhesion mediated by cadherin GO:0044331 9.16 CDH3 CDH1
5 cellular response to indole-3-methanol GO:0071681 8.96 CTNNA1 CDH1
6 adherens junction organization GO:0034332 8.8 CTNNA1 CDH3 CDH1

Molecular functions related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeletal protein binding GO:0008092 9.26 CDH3 CDH1
2 beta-catenin binding GO:0008013 9.16 CTNNA1 CDH1
3 cadherin binding GO:0045296 9.13 CTNNA1 CDH3 CDH1
4 gamma-catenin binding GO:0045295 8.62 CTNNA1 CDH1

Sources for Diffuse Gastric Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....